Celcuity (CELC) Receives a Buy from Stifel Nicolaus

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Celcuity, with a price target of $175.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Willey covers the Healthcare sector, focusing on stocks such as Incyte, Syndax Pharmaceuticals, and Crescent Biopharma. According to TipRanks, Willey has an average return of 9.5% and a 46.61% success rate on recommended stocks.

In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $155.00 price target.

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Celcuity (CELC) with a $175 price target. Additionally, H.C. Wainwright reiterated a Buy rating on the stock with a $155 price target.

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Celcuity, with a price target of $175.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $155.00 price target.